Articles Related to osteoblasts
High Glucose Modulates Responsiveness to Estrogens of Human Derived Female Cultured Osteoblasts and in Osteoblastic Cell Lines
Human female- derived osteoblast- like cells in culture (hObs) and the cell lines (SaOS2 and hFOB) express mRNAs involved in bone biology and physiology such as estrogen receptor α (ERα) and α (ERα), vitamin D receptor (VDR), 1α, 25 (OH) vitamin D3 hydroxylase (1OHase) and 12 and 15 lipoxygenases (12LO and 15LO). These mRNAs are modulated by estrogenic compounds. Since the skeletal protective effects of estrogens are not discernible in diabetic women, we tested the estrogenic modulations of these parameters in cells grown in growth medium containing high glucose (HG; 9.0g/L; 44mM) compared to normal glucose (NG; 4.5g/L; 22mM). HG significantly increased DNA synthesis (DNA) and creatine kinase specific activity (CK). Stimulations of DNA but not of CK by estradiol-17β (E2), by 4, 4’, 4’’-[4-propyl-(1H)-pyrazol-1, 3, 5- triyl] tris-phenol (PPT; ERa specific agonist), or by 2, 3-bis (4-hydroxyphenyl)-propionitrile (DPN; ER β specific agonist), were modulated by HG. HG Itself up regulated the expression of mRNA of 12LO and 15LO and to less extent ERβ and VDR, but had no effect on ERα and 1OHase mRNA expression. The different hormonal treatments modulated the expressions of VDR, 1OHase, 12LO and 15LO mRNAs which were reduced in HG, whereas the induction of their products 1α, 25 dihydroxy-vitamin D3 (1,25D) and 12- and 15- hydroxyeicosatetraenoic acid (12 and 15 HETE) were only slightly affected by HG. The exact mechanism of HG effects on bone cell responses and its relationship to human bone physiology is not yet clear.
Feasibility Analysis of Autogenous Tooth-based Bone Graft Material after Guided Bone Regeneration Technique
We set out to determine the possibility of radiographically evaluating the degree of marginal bone loss in humans after functional loading of implants at sites of guided bone regeneration (GBR) with autogenous tooth-based bone graft (ATBBG) material (AutoBT®, Korea Tooth Bank, Seoul, Korea).
Juvenile Ossifying Fibroma - WHO Type
Juvenile ossifying fibroma is an uncommon clinical entity, its aggressive local behaviour and high recurrence rate mean that it is important
to make an early diagnosis, apply the appropriate treatment and, especially, follow the patient up over the long term. In the
current article we report a case of juvenile ossifying fibroma-WHO type in 12yr old patient which was clinical and histopathologically
challenging as it was asymptomatic and at an unusual location.